LynparzaTM (olaparib) is a first‐in‐class PARP inhibitor (PARPi) that allows women with BRCA mutated (BRCAm) platinum‐sensitive relapsed high-grade serous ovarian cancer to extend progression‐free survival (PFS).1-3
About Study 19
For patients with BRCA mutation, Lynparza delays the need for subsequent treatment.4, 35
In patients with a BRCA mutation, Lynparza delayed the time from randomisation to start of first subsequent therapy or death (TFST)††, or when patients needed their next chemotherapy, by a median of 9.4 months (HR 0.32; 95% CI 0.22-0.48; p<0.0001; median 15.6 months vs 6.2 months).35
Adapted with permission from Ledermann.35
††An exploratory retrospective analysis.